NCT06771544View on ClinicalTrials.gov

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 23, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
MelanomaMelanoma Stage IIIMelanoma (Skin)Melanoma Stage IV
Interventions
DRUG

Pembrolizumab

Given IV

DRUG

Cyclophosphamide

Given PO

Trial Locations (1)

92868

RECRUITING

Chao Family Comprehensive Cancer Center University of California, Irvine, Orange

All Listed Sponsors
lead

University of California, Irvine

OTHER